JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE) ›› 2022, Vol. 42 ›› Issue (1): 130-134.doi: 10.3969/j.issn.1674-8115.2022.01.020

• Review • Previous Articles    

Research progress of Gd-EOB-DTPA-enhanced magnetic resonance imaging in the evaluation of biological behavior of hepatocellular carcinoma

Yihuan WANG(), Ruokun LI, Huanhuan CHONG, Fuhua YAN()   

  1. Department of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200032, China
  • Received:2021-08-19 Online:2022-01-28 Published:2022-02-18
  • Contact: Fuhua YAN E-mail:601434482@qq.com;yfh11655@rjh.com.cn
  • Supported by:
    Innovative Research Team of High-level Local Universities in Shanghai(SSMU-ZDCX20180101)

Abstract:

Hepatocellular carcinoma is the most common primary malignant tumor of liver tumors and ranked as the third leading cause of cancer death. Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) is a new hepatocyte-specific contrast agent commonly used at present. Its sensitivity and specificity for the diagnosis of small hepatocellular carcinoma can both be over 90%. Early diagnosis of hepatocellular carcinoma can benefit patients clinically, but as hepatocellular carcinoma is a highly heterogeneous tumor, the tumor biological behavior is also a key factor affecting the prognosis. Gd-EOB-DTPA-enhanced magnetic resonance imaging (EOB-MRI) can provide relevant information about identification of molecular typing, evaluation of immune microenvironment, and prediction of microvascular invasion and postoperative recurrence in hepatocellular carcinoma. This article reviews the research progress of EOB-MRI in the evaluation of biological behavior of hepatocellular carcinoma to provide reference for the diagnosis and treatment of hepatocellular carcinoma.

Key words: hepatocellular carcinoma (HCC), gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA), magnetic resonance imaging (MRI), molecular classification, β-catenin, immune microenvironment, microvascular invasion (MVI), recurrence

CLC Number: